Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Assets (2021 - 2025)

Historic Assets for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $43.7 million.

  • Lyra Therapeutics' Assets fell 4450.07% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 4450.07%. This contributed to the annual value of $66.3 million for FY2024, which is 5347.41% down from last year.
  • Lyra Therapeutics' Assets amounted to $43.7 million in Q3 2025, which was down 4450.07% from $52.6 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Assets high stood at $142.6 million for Q4 2023, and its period low was $43.7 million during Q3 2025.
  • Over the past 5 years, Lyra Therapeutics' median Assets value was $78.8 million (recorded in 2024), while the average stood at $89.2 million.
  • Per our database at Business Quant, Lyra Therapeutics' Assets skyrocketed by 10042.65% in 2022 and then tumbled by 6020.83% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Assets (Quarter) stood at $54.9 million in 2021, then skyrocketed by 100.43% to $110.0 million in 2022, then grew by 29.67% to $142.6 million in 2023, then plummeted by 53.47% to $66.3 million in 2024, then tumbled by 34.12% to $43.7 million in 2025.
  • Its Assets stands at $43.7 million for Q3 2025, versus $52.6 million for Q2 2025 and $56.3 million for Q1 2025.